Levocloperastine
Reading File
Finding Sources
Finding Sources
Searching the Web
Levocloperastine mechanism of action uses cough
Searching PubMed
levocloperastine cough
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC3061847
Levocloperastine
Class: Non-opioid antitussive (cough suppressant). It is the levorotatory enantiomer of cloperastine (a piperidine derivative, chemically related to diphenhydramine-type antihistamines), and has a pharmacological profile distinct from racemic DL-cloperastine.
Mechanism of action
Levocloperastine has a dual site of action:
- Central - acts on the bulbar cough centre in the medulla, similar in potency to codeine in preclinical models.
- Peripheral - acts on sensory (stretch/irritant) receptors in the tracheobronchial tree, giving it a peripheral antitussive/mild antispasmodic effect not shared by purely centrally-acting agents like codeine.
It also carries mild antihistaminic (H1) activity (inherited from the cloperastine/diphenhydramine-like structure), which contributes to symptom relief in allergic or irritant cough, and it does not act via opioid receptors, so it lacks respiratory depressant or abuse potential.
Indications
- Dry (nonproductive), irritating cough of varied etiology - upper/lower respiratory tract infections, chronic bronchitis, allergic conditions.
- Effective in ACE inhibitor-induced cough in adults.
- Used in both children and adults; in children it has been shown to reduce night-time awakenings and irritability associated with cough.
Efficacy/comparative data
Clinical trials and a pooled comparative analysis found levocloperastine had efficacy equal to or better than codeine, DL-cloperastine, and levodropropizine, with a notably faster onset of action (improvement often seen within the first day of treatment) (Aliprandi et al., Drugs Exp Clin Res 2004, PMID 15553659). A more recent prospective observational study (Satish et al., J Assoc Physicians India 2018, PMID 30477064) also supports efficacy and safety in dry cough, including quality-of-life improvement.
Safety/tolerability
- Generally well tolerated; no significant CNS depression or notable drowsiness reported in comparative trials (a clear advantage over codeine, which commonly caused drowsiness in the same studies).
- No evidence of respiratory depression or abuse potential (non-opioid).
- Mild antihistaminic-related sedation is theoretically possible but not prominent in trials.
Related agent - cloperastine (racemic parent compound)
Since dedicated levocloperastine pharmacokinetic data is limited in indexed literature, general cloperastine data (its parent racemate) is informative: onset ~20-30 minutes after oral dosing, duration of action 3-4 hours, typical adult dose historically 10-20 mg three times daily (formulation-dependent); a single 20 mg evening dose has also been used to improve night-time cough without daytime sedation (Catania & Cuzzocrea, Ther Clin Risk Manag 2011, PMID 21445282).
Note on sources
This drug is not covered in the standard textbooks in the medical library (Goodman & Gilman's Pharmacology, Murray & Nadel's Respiratory Medicine) - those cover antitussives broadly (opioid agents, dextromethorphan, benzonatate) but do not specifically index levocloperastine or cloperastine. The information above is drawn from PubMed-indexed clinical/pharmacology literature rather than the textbook library.
- Aliprandi P et al. Levocloperastine in the treatment of chronic nonproductive cough: comparative efficacy versus standard antitussive agents. PMID 15553659
- Satish K et al. Efficacy and Safety of Levocloperastine in the Treatment of Dry Cough. PMID 30477064
- Catania MA, Cuzzocrea S. Pharmacological and clinical overview of cloperastine in treatment of cough. PMID 21445282
If you want, I can look into specific dosing by country/brand (it's marketed in various formulations, e.g., "Levotuss", "Lastux") or its use in a particular clinical scenario (pediatric dosing, drug interactions, pregnancy safety).
Compare levocloperastine vs codeine and dextromethorphan
Finding Sources
Finding Sources
Searching PubMed
levocloperastine AND dextromethorphan
Searching the Web
levocloperastine vs dextromethorphan vs codeine comparison cough efficacy safety
Levocloperastine vs. Codeine vs. Dextromethorphan
All three are used as antitussives (cough suppressants), but they differ meaningfully in mechanism, receptor pharmacology, abuse potential, and comparative efficacy.
1. Drug class and mechanism of action
| Feature | Levocloperastine | Codeine | Dextromethorphan |
|---|---|---|---|
| Class | Non-opioid, piperidine derivative (levo-enantiomer of cloperastine) | Opioid (natural phenanthrene, mu-opioid receptor agonist) | Non-opioid, synthetic morphinan (dextro-isomer, stereoisomer of levorphanol) |
| Primary site of action | Dual: central bulbar cough centre + peripheral sensory receptors in the tracheobronchial tree | Central: depresses the medullary cough centre via mu-opioid receptors (though part of its antitussive action may be independent of opioid receptors) | Central: cough centre suppression, mediated at least partly via NMDA receptor antagonism and sigma-1 receptor binding rather than classical opioid receptors |
| Secondary activity | Mild H1-antihistaminic activity (shares an ethylamine moiety with diphenhydramine-type antihistamines); mild bronchorelaxant/antispasmodic effect | Analgesic, mild sedative, constipating (typical opioid effects) | Weak serotonin reuptake inhibition; essentially no analgesic activity at antitussive doses |
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
- Goodman & Gilman's Pharmacological Basis of Therapeutics - Opioid-Related Antitussive Agents
- Lippincott Illustrated Reviews Pharmacology - Codeine/Dextromethorphan
2. Efficacy
- Levocloperastine vs. dextromethorphan: A randomized, open-label phase IV trial found levocloperastine (20 mg/5 mL syrup, TID) significantly reduced cough severity/frequency and improved Leicester Cough Questionnaire scores more than dextromethorphan (5 mg lozenges, TID) at day 7 (Int J Basic Clin Pharmacol, ijbcp.com).
- Levocloperastine vs. codeine: Comparative clinical data show levocloperastine has efficacy equal to or better than codeine, with a faster onset of action (improvement often within the first day) and no significant drowsiness, unlike codeine (Aliprandi et al., PMID 15553659).
- Preclinical (guinea pig) model: Cloperastine (levocloperastine's parent/related compound) and codeine both significantly reduced cough intensity and delayed cough onset comparably; codeine showed the longest delay to first cough (~311 s), cloperastine close behind (~253 s), while dextromethorphan's effect was more modest (~218 s) and did not significantly reduce overall cough intensity in this model (Comparative Analysis of Classic and Novel Antitussives, PMC12655678).
- Dextromethorphan is the only OTC agent to show objective suppression of acute cough in some controlled measures, but multiple studies (and the Cochrane-style literature on acute URTI cough) have found it performs no better than placebo in several trials, and codeine likewise failed to beat placebo for cough associated with the common cold in controlled studies.
3. Safety, tolerability, and abuse potential
| Feature | Levocloperastine | Codeine | Dextromethorphan |
|---|---|---|---|
| Sedation/drowsiness | Minimal to none reported in trials | Common (notable drowsiness reported in comparative trials) | Generally mild at therapeutic doses |
| Respiratory depression | No | Yes (dose-dependent, opioid effect) | No at therapeutic doses |
| GI effects (nausea, constipation) | Rare | Common | Uncommon |
| Abuse/dependence potential | None (non-opioid) | Yes (opioid; regulated/restricted in many countries) | Yes, at supratherapeutic doses (dissociative/hallucinogenic effects via NMDA antagonism; recreational misuse reported) |
| Pediatric use | Used in children; reduces night-time awakenings/irritability | Not recommended under 12 (FDA/EMA restrictions due to respiratory depression risk) | FDA advises against OTC cough/cold products, including dextromethorphan, in children under 2; caution 2-11 years |
| Special utility | Effective in ACE-inhibitor-induced cough | Historically the "gold standard" comparator, but with abuse/regulatory concerns leading many markets to restrict OTC codeine | Widely available OTC; preferred over codeine in many countries specifically because of lower abuse liability, though still misused in high doses |
4. Bottom line
- Mechanistically, levocloperastine is unique in combining central and peripheral antitussive action plus mild antihistaminic effect, whereas codeine and dextromethorphan act predominantly centrally (opioid vs. NMDA/sigma-1 pathways respectively).
- Efficacy-wise, levocloperastine has outperformed dextromethorphan in a head-to-head RCT and matched or exceeded codeine in older comparative trials, with a quicker onset in both cases.
- Safety-wise, levocloperastine's non-opioid, non-sedating profile gives it an advantage over codeine (sedation, dependence, respiratory depression risk) and a comparable or better safety margin than dextromethorphan (which carries dissociative/misuse risk at high doses and inconsistent efficacy evidence in acute viral cough).
Caveat: The evidence base for levocloperastine is comparatively small (mostly Italian/Indian trials, some older, with a few open-label or unblinded designs), and it is not available in many countries (including the US), where dextromethorphan and codeine remain the dominant options. Larger, high-quality head-to-head RCTs are limited, so these comparative conclusions should be interpreted with that in mind.
Sources:
- Aliprandi P et al., Drugs Exp Clin Res 2004 (PMID 15553659)
- Satish K et al., J Assoc Physicians India 2018 (PMID 30477064)
- Comparison of safety and efficacy of dextromethorphan and levocloperastine, Int J Basic Clin Pharmacol
- Comparative Analysis of Classic and Novel Antitussives on Cough Suppression in Guinea Pigs, PMC12655678
- Catania MA, Cuzzocrea S. Ther Clin Risk Manag 2011 (PMID 21445282)
- Katzung's Basic and Clinical Pharmacology, 16th Ed. - Antitussives
- Goodman & Gilman's Pharmacological Basis of Therapeutics - Opioid-Related Antitussive Agents
- Lippincott Illustrated Reviews Pharmacology - Codeine and Dextromethorphan
- Murray & Nadel's Textbook of Respiratory Medicine - Narcotic and Non-Narcotic Antitussives
This is a shared conversation. Sign in to Orris to start your own chat.